PTC 209 NEW

A small molecule inhibitor of polycomb complex protein BMI-1, a gene often overexpressed in tumors and therefore a popular therapeutic target in cancer. Anti-tumor effects of PTC 209 have been demonstrated in colorectal carcinoma, acute myeloid leukemia, multiple myeloma and head neck squamous cell carcinoma. As a regulator of self-renewal, inhibition of BMI-1 by PTC 209 also reduces growth of colorectal cancer initiating cells.

Size	Surcharge	Price	Quantity
10 mg	TBC TBC TBC	$135.00 �106.70 €120.20	Add Check Stock
50 mg	TBC TBC TBC	$472.50 �373.50 €420.50	Add Check Stock
	TBC TBC TBC	$ � €	Add Check Stock
	TBC TBC TBC	$ � €	Add Check Stock
	TBC TBC TBC	$ � €	Add Check Stock
Custom Pack
	TBC TBC TBC	$�€ 0.00	Enter a pack size. Add Check Stock

Technical Data

CAS No:	315704-66-6
Product Code:	BP165815
MDL No:	MFCD02110649
Chemical Formula:	C₁₇H₁₃Br₂N₅OS
Molecular Weight:	495.19

References

Kreso A et al (2014). Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 20(1):29-36.
Bolomsky A et al (2016). Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. J Hematol Oncol 9:17.
Wang Q et al (2017). Pharmacological inhibition of Bmi1 by PTC-209 impaired tumor growth in head neck squamous cell carcinoma. Cancer Cell Int 17:107.